Skip to content
Ultromics logo — Ultromics is transforming the detection of heart failure usi...

Ultromics

Ultromics is transforming the detection of heart failure using artificial intelligence for echocardiography.

Founded 2017 United Kingdom Oxford, United Kingdom 85 employees Series C Total: $93.70M AI, Computer Vision +1

General Information

Company Name Ultromics
Founded Year 2017
Location United Kingdom Oxford, United Kingdom
Employees 85
Industries AI, Computer Vision, Health Care
Funding Stage Series C
Business Model B2B, SaaS, Platform
Revenue Model Usage Based, Subscription
Social

BounceWatch is an independent company data service, not affiliated with Ultromics. To contact Ultromics, visit ultromics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Ultromics compare?

A PDF of Ultromics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Ultromics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Ultromics

Ultromics, founded in 2017, is at the forefront of revolutionizing heart failure detection through its innovative use of artificial intelligence in echocardiography. Headquartered in the United Kingdom, the company stands out within the AI, Computer Vision, and Health Care industries.

Their flagship product, EchoGo®, leverages one of the world's largest heart disease datasets to provide precision diagnostics for heart failure, particularly tackling complex conditions such as HFpEF. The platform's ability to deliver precise and efficient assessments is bolstered by strategic collaborations with prestigious partners such as the Mayo Clinic, Johnson & Johnson, and Pfizer.

Ultromics recently secured a €48.00M Series C investment on 31 July 2025 from a distinguished group of investors, including Blue Venture Fund, GV, Lightrock, Allegis Capital, and others, reflecting strong market confidence in its disruptive potential.

Business keywords: artificial_intelligence, echocardiography, heart_failure_detection, precision_medicine, cardiac_ultrasound, HFpEF, clinical_diagnostics, healthcare_technology, medical_imaging, cardiology, partnership_with_mayo_clinic, partnership_with_johnson_and_johnson, partnership_with_pfizer, early_intervention, heart_disease_dataset

Services & Products

AI-powered HFpEF detection
AI-powered Cardiac Amyloidosis detection
EchoGo® Integration and analytics
Automated diagnostic reporting

Target Customers

Healthcare Institutions Cardiologists Clinical Decision Support Teams Hospitals and Clinics

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series C €48.00M 9
Blue Venture Fund, GV +7
31 Jul 2025
Series B £23.70M 4
GV, Optum Ventures +2
16 Aug 2021
Series A $10.00M 1
Nina Ventures
15 Jun 2020
Venture Round Undisclosed 1
Future Planet Capital
01 Nov 2019
Series A £10.00M 4
GT Healthcare Capital Partners, RT Ventures +2
22 May 2018
Seed Round £2.00M -
01 May 2017

Ultromics Alternatives & Competitors

View All Alternatives
Ultromics vs
Carelog
Carelog United States

Innovation begins at heart

Pre-Seed
4 employees
AI, Health Care
Ultromics vs

The only AI-based multiorgan product for early diagnosis and non-invasive monitoring of abdominal ca...

Grant
22 employees
AI, Health Care
Ultromics vs
RareSum
RareSum Turkey

Empowering Healthcare Professionals with AI-powered research and decision-support solutions for Rare...

8 employees
AI, Health Care

FAQ About Ultromics

Ultromics is transforming the detection of heart failure using artificial intelligence for echocardiography.
Ultromics was founded in 2017.
Ultromics is headquartered in Oxford, United Kingdom.
Ultromics operates in AI, Computer Vision and Health Care. Its work centres on artificial_intelligence, echocardiography, heart_failure_detection and precision_medicine. Its customers include Healthcare Institutions, Cardiologists and Clinical Decision Support Teams.
Ultromics has a B2B, SaaS and Platform business model. Its revenue comes from Usage Based and Subscription.
Ultromics has approximately 85 employees.
Ultromics has completed 6 funding rounds, raising a total of $93.70M. The latest funding stage is Series C.
Ultromics offers: AI-powered HFpEF detection, AI-powered Cardiac Amyloidosis detection, EchoGo® Integration and analytics, Automated diagnostic reporting.
Top alternatives and competitors to Ultromics include Carelog, Sycai Medical, RareSum, Kepler Vision Technologies, Us2.ai. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ultromics and Carelog are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ultromics, https://bouncewatch.com/company/ultromics, updated 29 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout